mTOR inhibitor, everolimus, demonstrated efficacy in combination with ET in advanced BC and is generally believed to reverse endocrine resistance by inhibition of mTORC-1-dependent phosphorylation of ERα, but de-repression of PgR expression may represent another possible mechanism of action [87,88,89]. Here, ESR1 is linked to breast cancer.